

## **HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS**

### **PRIOR AUTHORIZATION FORM** (form effective 1/8/2024)

Prior authorization guidelines for **Hypoglycemics, Incretin Mimetics/Enhancers** and **Quantity Limits/Daily Dose Limits** are available on Geisinger Health Plan's website at <https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger>

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request	total # of pgs: _____	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:

### **CLINICAL INFORMATION**

Drug requested:	Strength:	Dosage form:	
Dose/directions:		Quantity:	Refills:
Diagnosis ( <u>submit documentation</u> ):		DX code ( <u>required</u> ):	

**Complete all sections that apply to the beneficiary and this request.**

**Check all that apply and submit documentation for each item.**

#### **INITIAL requests**

##### **1. For a non-preferred GLP-1 RECEPTOR AGONIST for the treatment of OBESITY:**

☐ Tried and failed or has a contraindication or an intolerance to the preferred GLP-1 receptor agonists on the Statewide Preferred Drug List that are approved or medically accepted for the beneficiary's diagnosis or indication (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred GLP-1 receptor agonists.)

☐ **Attestation from the prescriber:**

☐ The beneficiary was counseled about lifestyle changes and behavior modifications such as a healthy diet and increased physical activity

☐ **The beneficiary is 18 years of age or older:**

Pre-treatment weight: \_\_\_\_\_ Pre-treatment BMI: \_\_\_\_\_

☐ Has a BMI greater than or equal to 30 kg/m<sup>2</sup>

☐ Has a BMI greater than or equal 27 kg/m<sup>2</sup> and less than 30 kg/m<sup>2</sup> and at least one of the following weight-related comorbidities:

☐ dyslipidemia

☐ obstructive sleep apnea

☐ hypertension

☐ prediabetes

☐ metabolic syndrome

☐ type 2 diabetes

☐ other (list): \_\_\_\_\_

☐ Is a candidate for treatment based on degree of adiposity, waist circumference, history of bariatric surgery, BMI exceptions for

beneficiary's ethnicity, etc. and has at least one of the following weight-related comorbidities:

- |  |  |
|--|--|
| <input type="checkbox"/> dyslipidemia        | <input type="checkbox"/> obstructive sleep apnea |
| <input type="checkbox"/> hypertension        | <input type="checkbox"/> prediabetes             |
| <input type="checkbox"/> metabolic syndrome  | <input type="checkbox"/> type 2 diabetes         |
| <input type="checkbox"/> other (list): _____ |  |

☐ The beneficiary is **less than 18 years of age**:

Pre-treatment BMI: \_\_\_\_\_ Pre-treatment BMI z-score: \_\_\_\_\_

☐ Has a BMI in the 95<sup>th</sup> percentile or greater standardized for age and sex based on current CDC charts

**2. For the treatment of ALL OTHER diagnoses:**

☐ Request is for a non-preferred **GLP-1 receptor agonist**:

☐ Tried and failed or has a contraindication or an intolerance to the preferred Hypoglycemics, Incretin Mimetics/Enhancers GLP-1 receptor agonists that are approved or medically accepted for the beneficiary's diagnosis or indication (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred Hypoglycemics, Incretin Mimetics/Enhancers GLP-1 receptor agonists.)

☐ Request is for a non-preferred **DPP-4 inhibitor**:

☐ Tried and failed or has a contraindication or an intolerance to the preferred Hypoglycemics, Incretin Mimetics/Enhancers DPP-4 inhibitors that are approved or medically accepted for the beneficiary's diagnosis or indication (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred Hypoglycemics, Incretin Mimetics/Enhancers DPP-4 inhibitors.)

☐ Request is for non-preferred **Symlin (pramlintide)**

**RENEWAL requests**

☐ For a non-preferred **GLP-1 RECEPTOR AGONIST** for the treatment of **OBESITY**:

☐ Tried and failed or has a contraindication or an intolerance to the preferred GLP-1 receptor agonists on the Statewide Preferred Drug List that are approved or medically accepted for the beneficiary's diagnosis or indication (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred GLP-1 receptor agonists.)

☐ The dose of the requested medication is currently being titrated

☐ The beneficiary is experiencing clinical benefit with the requested medication

☐ Attestation from the prescriber:

☐ The beneficiary was counseled about lifestyle changes and behavior modifications such as a healthy diet and increased physical activity

☐ The beneficiary is **18 years of age or older**:

Pre-treatment weight: \_\_\_\_\_ Current weight: \_\_\_\_\_

☐ The beneficiary is **less than 18 years of age**:

Pre-treatment BMI: \_\_\_\_\_ Current BMI: \_\_\_\_\_

Pre-treatment BMI z-score: \_\_\_\_\_ Current BMI z-score: \_\_\_\_\_

☐ The beneficiary is being treated for a diagnosis **OTHER THAN OBESITY**.

Please submit to PromptPA <https://ghp.promptpa.com> OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.

Prescriber Signature:

Date:

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.